【摘要】：目的 :探討不同添加時(shí)間、療程及劑量益生菌在根除幽門(mén)螺桿菌(helicobacter pylori,Hp)治療中的臨床療效。方法:280例Hp陽(yáng)性的患者隨機(jī)分為5個(gè)治療組:A組:蘭索拉唑片30 mg+克拉霉素片500mg+阿莫西林膠囊1 000 mg,每日2次,療程14 d;B組:雙歧桿菌乳桿菌三聯(lián)活菌片(2 000 mg,每日3次)服用14 d后,給予A組治療方案治療14 d,總療程28 d;C_1組:A組治療方案基礎(chǔ)上加用雙歧桿菌乳桿菌三聯(lián)活菌片(2 000 mg,每日2次),療程14 d;C_2組:A組治療方案基礎(chǔ)上加用雙歧桿菌乳桿菌三聯(lián)活菌片(2 000 mg,每日3次),療程14 d;D組:C_2組方案根除治療后,繼續(xù)用雙歧桿菌乳桿菌三聯(lián)活菌片(2 000 mg,每日3次)14 d,總療程28 d。療程結(jié)束4周后復(fù)查~(13)C尿素呼氣試驗(yàn)評(píng)估根除療效。治療期間記錄患者的不良反應(yīng)發(fā)生情況。結(jié)果:252例(90.0%)患者按方案完成治療,A、B、C_1、C_2、D組治療完成率分別為78.6%(44/56)、92.9%(52/56)、87.5%(49/56)、96.4%(54/56)和94.6%(53/56),B、C_2及D組顯著高于A組(P0.05),而C_2略高于B及D組,但差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。A、B、C_1、C_2及D組按意向治療(ITT)根除率分別為62.5%、80.4%、69.6%、85.7%和87.5%,B、C_2及D組顯著高于A組(χ~2=4.375,P=0.036;χ~2=7.864,P=0.005;χ~2=9.333,P=0.002),且C_2組高于C_1組(χ~2=4.171,P=0.041),而D組稍高于B組及C_2組,但差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05);按方案治療(PP)五組根除率分別為79.5%、86.5%、79.6%、88.9%和92.5%,各組間差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。不良反應(yīng)包括惡心、腹脹、味覺(jué)異常(口苦、口腔異味)、厭食及便秘等。A、B、C_1、C_2及D組不良反應(yīng)的發(fā)生率分別為67.9%(38/56)、26.8%(15/56)、35.7%(20/56)、21.4%(12/56)及17.9%(10/56),B、C_2及D組明顯少于A組(P0.05),而B(niǎo)、C_2及D組各組間的差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:三聯(lián)療法聯(lián)合雙歧桿菌乳桿菌三聯(lián)活菌能夠顯著降低傳統(tǒng)根除療法的胃腸道不良反應(yīng),提高患者依從性,從而提高患者Hp的根除率,且隨著益生菌劑量的增加,Hp的根除率也隨之增加,同時(shí)服用益生菌14 d為最佳選擇。
[Abstract]:Objective: to investigate the clinical efficacy of probiotics at different time, course and dose in the eradication of helicobacter pylorium-HP. Methods one hundred and twenty patients with HP positive were randomly divided into 5 groups: group A: lansoprazole 30 mg clarithromycin tablet 500mg amoxicillin capsule 1 000 mg twice a day. Group B was treated with bifidobacterium Lactobacillus triple live bacteria tablet (2 000 mg, 3 times a day) for 14 days. Group A was given the treatment regimen for 14 days, and the total course of treatment was 28 days. Group 1: group A was treated with bifidobacterium Lactobacillus triple live bacteria tablet (2 000 mg, twice a day) on the basis of the treatment plan of group 1: a, and bifidobacterium milk was added to the treatment plan of group C 2: a for 14 days. Three live bacilli tablets (2 000 mg, 3 times a day) for 14 days, group D, group 1: C, group C, group 2, after eradication treatment, Bifidobacterium Lactobacillus triplex live bacteria tablets (2 000 mg, 3 times a day) for 14 days, the total course of treatment was 28 days. The eradication effect was evaluated by ~ (13) C urea breath test after 4 weeks of treatment. Adverse reactions were recorded during treatment. Results among 252 patients (90.0%), the complete rate of treatment in group C was 78.6% (44 / 56) or 92.9% (5256), respectively, 87.5% (54 / 56) and 94.6% (53 / 56) of BC2 and group D were significantly higher than those of group A (P0.05), while the rate of C2C2 was slightly higher than that of group B and D. However, there was no significant difference between the two groups (P0.05). The eradication rates of (ITT) in group D and group C were 62.5 and 89.60.45%, respectively, which were significantly higher than those in group A (蠂 2 4.375P0.036; 蠂 2 7.864 P 0.005; 蠂 2 9.333P 0.002), and in group C2 higher than those in group C1 (蠂 24.171P0. 041), while group D was slightly higher than those in group B and group C2, and in group D they were higher than those in group C (P < 0.05), but in group D were higher than those in group C (P < 0.05), but no significant difference was found between group C and group D (P 0.05). The eradication rate of (ITT) in group C was higher than that in group C 1 (P < 0.05), but that in group D was slightly higher than that in group C and group B (P 0.036; P 0.036; 蠂 2 9.333P 0.002). But the difference was not statistically significant (P0.05); the eradication rate of the five groups of (PP) was 79.5% and 92.5%, respectively. There was no significant difference among the five groups (P0.05). The incidence of adverse reactions including nausea, abdominal distension, abnormal taste (bitter mouth, mouth odour), anorexia and constipation were 67.9% (38 / 56), 26.8% (15 / 56) and 35.7% (20 / 56), respectively. The incidence of adverse reactions in group B and D was significantly lower than that in group A (P0.05). Conclusion: triple therapy combined with living bacteria of Lactobacillus bifidobacterium can significantly reduce gastrointestinal adverse reactions of traditional eradication therapy, improve compliance of patients, and thus improve the eradication rate of HP in patients. The eradication rate of HP increased with the increase of probiotic dose, and the best choice was to take probiotics for 14 days.
【作者單位】： 廣東藥學(xué)院附屬第二醫(yī)院(廣州新海醫(yī)院)消化內(nèi)科;廣東省醫(yī)學(xué)科學(xué)院 廣東省人民醫(yī)院消化內(nèi)科;
【基金】：廣東省醫(yī)學(xué)科學(xué)技術(shù)研究基金項(xiàng)目(編號(hào):A2016406)
【分類(lèi)號(hào)】：R57

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 習(xí)羽;潘冬梅;;探討丹參針劑輔助治療急性水腫型胰腺炎患者的臨床療效[J];求醫(yī)問(wèn)藥(下半月);2012年10期

2 廖茂杰;;應(yīng)用中西醫(yī)結(jié)合的方法治療急性上消化道出血的臨床療效觀察[J];求醫(yī)問(wèn)藥(下半月);2013年06期

3 徐文進(jìn);中西醫(yī)結(jié)合治療脾虛型慢性潰瘍性結(jié)腸炎98例的臨床療效觀察[J];中國(guó)中西醫(yī)結(jié)合脾胃雜志;1994年02期

4 韓麗芳;復(fù)肝康方劑的臨床療效觀察[J];長(zhǎng)治醫(yī)學(xué)院學(xué)報(bào);1997年01期

5 王劍;王繼海;;76例慢性乙型病毒性肝炎中西醫(yī)結(jié)合治療體會(huì)[J];當(dāng)代醫(yī)學(xué);2012年04期

6 李曉龍;楊柏建;;調(diào)脂護(hù)肝方配合西藥治療非酒精性脂肪性肝病臨床療效觀察[J];寧夏醫(yī)學(xué)雜志;2013年06期

7 鄭廣華;;同化激素治療潰瘍病的臨床療效[J];國(guó)外醫(yī)學(xué)參考資料(內(nèi)科學(xué)分冊(cè));1976年08期

8 殷衛(wèi)衛(wèi);腺苷蛋氨酸治療病毒性淤膽型肝炎臨床療效觀察[J];江蘇醫(yī)藥;1999年06期

9 白勇剛;白智剛;;加味蘇子降氣湯聯(lián)合西沙必利治療46例便秘臨床療效觀察[J];內(nèi)蒙古中醫(yī)藥;2011年01期

10 張卓;;中西醫(yī)結(jié)合治療急性上消化道出血臨床療效觀察[J];齊齊哈爾醫(yī)學(xué)院學(xué)報(bào);2012年18期

相關(guān)會(huì)議論文 前4條

1 田一梅;王憲波;李晶瑩;張佳瑩;郝新潔;姚鵬;李秀惠;;中西醫(yī)結(jié)合治療618慢性乙型重型肝炎臨床療效分析[A];全國(guó)第3屆中西醫(yī)結(jié)合傳染病學(xué)術(shù)會(huì)議暨中國(guó)中西醫(yī)結(jié)合學(xué)會(huì)傳染病專(zhuān)業(yè)委員會(huì)第2屆委員會(huì)議論文匯編[C];2010年

2 侯巖;張明香;李莉;崔麗萍;;中西醫(yī)結(jié)合治療肝硬化頑固性腹水的臨床療效觀察[A];全國(guó)第4屆中西醫(yī)結(jié)合傳染病學(xué)術(shù)會(huì)議論文匯編[C];2012年

3 溫小鳳;柯柳;;膽紅素特異性吸附治療肝炎高膽紅素血癥的臨床療效[A];第三屆全國(guó)重型肝病及人工肝血液凈化學(xué)術(shù)年會(huì)論文集（下冊(cè)）[C];2007年

4 劉景泉;;中西醫(yī)結(jié)合治療功能消化不良41例臨床療效分析[A];中國(guó)中西醫(yī)結(jié)合學(xué)會(huì)第十八次全國(guó)消化系統(tǒng)疾病學(xué)術(shù)會(huì)議暨2006年全國(guó)中西醫(yī)結(jié)合消化系統(tǒng)疾病進(jìn)展學(xué)習(xí)班論文匯編[C];2006年

，

本文編號(hào)：2184992